TrialNature communications2025

Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies.

Maurizio Callari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.